There is a new diabetes type II drug called, dapagliflozin, that will be marketed in the US this month under the name, Farxiga. The medication has already been sold in 38 other countries outside the US. As previously mentioned, this medication is strictly for Type II diabetes. It has been studied for its monotherapy, as well as for its combination therapy with other diabetes medications, including metformin, pioglitazone, glimepiride, sitagliptin, and insulin. Patients who have bladder cancer should not use this medication as some participants of the study developed bladder cancer. One of the most common adverse effects reported was genital fungal infections and urinary tract infections.
The recommended dose is to start off with 5mg tablet once a day in the morning either with or without food. If that does not work, then take 10mg per day.
Dapagliflozin comes in 5mg and 10mg tablets in 30, 90, or 500 tablet-bottles.
My thoughts: Another drug added to the list. The bladder cancer developments in participants alarm me and I’m surprised at how nonchalantly the article took it. I expected more of a serious warning. It did make me reflect on my health condition though as the article stated that dehydration and hypotension can be due to poor kidneys. I feel I am constantly dehydrated no matter how much water I take in and my skin is always dry. That makes me note the condition of my kidneys, which leaves me to think I have to eat more unseasoned foods with less sugar and less salt.
Article Source: American Society of Health-system Pharmacists